BLU-956 / Blueprint Medicines - LARVOL DELTA

Antitumor activity of potent and selective CDK2 inhibitors as monotherapy and in combination with chemotherapy in models of small cell lung cancer (AACR 2025) - P1/2 | "CDK2 inhibition represents a novel therapeutic approach in SCLC, an aggressive cancer with high unmet medical need. In pre-clinical models of SCLC, BLU-222 and BLU-956 demonstrated substantial anti-tumor activity as single agents, with enhanced effects in combination with cisplatin. These findings provide rationale for exploring targeting CDK2 in combination with cisplatin in SCLC and suggest that specific biomarkers could be useful to predict response."

Combination therapy • Monotherapy • Eye Cancer • Lung Cancer • Oncology • Retinoblastoma • Small Cell Lung Cancer • Solid Tumor • CCNE1 • CDK4 • CDKN2A • RB1 • SKP2